QRD Recommendations pack design & labelling …
QRD recommendations on pack design and labelling for centrally authorised non-prescription human medicinal products . 12 13 14 15 16 17 18 19 20
Download QRD Recommendations pack design & labelling …
Information
Domain:
Source:
Link to this page:
Documents from same domain
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Related documents
Excipients and information for the package leaflet EN
www.ema.europa.eu9 October 2017 EMA/CHMP/302620/2017 Annex to the European Commission guideline on ‘Excipients in the labelling and package leaflet of medicinal products for human use’ (SANTE-2017-11668)
Registration of Medicines Stability - ICH Official …
www.ich.orgRegistration of Medicines Stability Stability v1.doc March 2004 1 SADC GUIDELINE FOR STABILITY TESTING 2004 This guideline is intended to provide requirements to applicants wishing to submit
Medicines Control Council : General Information
www.kznhealth.gov.zaRegistration of Medicines General Information 2.01 General information Feb08 v4.doc April 2008 Page1 of 48 MEDICINES CONTROL COUNCIL GENERAL INFORMATION
Guideline on the Regulation of Therapeutic …
www.medsafe.govt.nzGuideline on the Regulation of Therapeutic Products in New Zealand Part 6: Bioequivalence of medicines Edition 2.0 February 2018
Guideline for the labelling of medicines
www.tga.gov.auGuideline for the labelling medicines of istorical consultation document Draft - Version 1.0, August 2014
GUIDELINE ON SUBMISSION OF …
www.who.intWorking document QAS/10.375 page 2 36 SCHEDULE FOR THE PROPOSED ADOPTION PROCESS OF DOCUMENT 37 QAS/10.375: 38 Drafting of guideline by G. Condran and L. Paleshnuik 7 June 2010
Related search queries
Guideline, Labelling, Registration of Medicines Stability, Medicines Control Council : General Information, Of Medicines, MEDICINES CONTROL COUNCIL GENERAL INFORMATION, Bioequivalence of medicines, Guideline for the labelling of medicines, Guideline for the labelling medicines, GUIDELINE ON SUBMISSION OF